

Electronic Supplementary Information (ESI)

Fungal biofilm inhibitors from a human oral microbiome-derived bacterium†

Xiaoru Wang,†^a Lin Du,†^a Jianlan You,^a Jarrod B. King,^a Robert H. Cichewicz*^{a,b}

^aNatural Products Discovery Group, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, 101 Stephenson Parkway, University of Oklahoma, Norman, OK, 73019, U.S.A. E-mail: rhcichewicz@ou.edu; Tel: +1 (405) 325-6969

^bGraduate Program in Ecology and Evolutionary Biology, University of Oklahoma, Norman, OK, USA, 73019, USA

† These authors contributed equally to this work.

Contents

Table S1. Revised ^1H -NMR and ^{13}C -NMR NMR data for mutanobactin A (**1**) (500 and 100 MHz, $\text{DMSO-}d_6$).

Fig. S1. HRESIMS of mutanobactin B (**2**).

Fig. S2. ^1H -NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S3. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S4. $^1\text{H-}^{13}\text{C}$ HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S5. $^1\text{H-}^{13}\text{C}$ HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S6. $^1\text{H-}^1\text{H}$ COSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S7. $^1\text{H-}^1\text{H}$ TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S8. $^1\text{H-}^1\text{H}$ NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).

Fig. S9. FTIR spectrum of mutanobactin B (**2**).

Fig. S10. HRESIMS of mutanobactin C (**3**).

Fig. S11. ^1H -NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S12. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S13. $^1\text{H-}^{13}\text{C}$ HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S14. $^1\text{H-}^{13}\text{C}$ HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S15. ^1H - ^1H COSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S16. ^1H - ^1H TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S17. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).

Fig. S18. FTIR spectrum of mutanobactin C (**3**).

Fig. S19. HRESIMS of mutanobactin D (**4**).

Fig. S20. ^1H -NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S21. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S22. ^1H - ^{13}C HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S23. ^1H - ^{13}C HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S24. ^1H - ^1H COSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S25. ^1H - ^1H TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S26. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).

Fig. S27. FTIR spectrum of mutanobactin D (**4**).

Fig. S28. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of [$1\text{-}^{13}\text{C}$]acetate labeled mutanobactin A.

Fig. S29. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of [$2\text{-}^{13}\text{C}$]acetate labeled mutanobactin A.

Fig. S30. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of [^{15}N , $^{13}\text{C}_2$]glycine labeled mutanobactin A.

Fig. S31. ^1H -NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin A (**1**).

Fig. S32. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin A (**1**).

Fig. S33. FTIR spectrum of mutanobactin A (**1**).

Fig. S34. Marfey's analysis of FDAA derivatized amino acid standards for the D and L forms of Aaba, Ala, Ile, Leu, Pro, and Val.

Fig. S35. Marfey's analysis of FDAA derivatized hydrolysates of **2**.

Fig. S36. Marfey's analysis of FDAA derivatized hydrolysates of **3**.

Fig. S37. Marfey's analysis (gradient elution) of FDAA derivatized hydrolysates of **4**.

Fig. S38. Marfey's analysis (isocratic elution) of FDAA derivatized hydrolysates of **4**.

Fig. S39. Proposed biosynthetic pathways for the mutanobactins.

Table S1. Revised ^1H -NMR and ^{13}C -NMR NMR data for mutanobactin A (**1**) (500 and 100 MHz, DMSO- d_6) – Shifts shown in **red** have been revised.

position	Mutanobactin A (1) (original)		Mutanobactin A (1) (revised)	
	δ_{C}	δ_{H} mult. (J in Hz)	δ_{C}	δ_{H} mult. (J in Hz)
1	50.4, CH	4.43 ddd (3.7, 9.0, 11.0)	50.4, CH	4.43 ddd (3.7, 9.0, 11.0)
2a	40.4, CH ₂	1.44, m	40.4, CH ₂	1.44, m
2b		1.81, ddd (3.9, 10.5, 13.8)		1.81, ddd (3.9, 10.5, 13.8)
3	24.2, CH	1.59, m	24.2, CH	1.59, m
4	20.9, CH ₃	0.82, d (6.6)	20.9, CH ₃	0.82, d (6.6)
5	23.5, CH ₃	0.92, d (6.7)	23.5, CH ₃	0.92, d (6.7)
6	170.5, C		170.5, C	
7	48.0, CH	4.52, q (6.8)	48.0, CH	4.52, q (6.8)
8	17.7, CH ₃	1.17, d (6.7)	17.7, CH ₃	1.17, d (6.7)
9	169.7, C		169.7, C	
10	61.0, CH	4.12, dd (3.7, 8.9)	61.0, CH	4.12, dd (3.7, 8.9)
11a	29.6, CH ₂	1.72, m	29.6, CH ₂	1.72, m
11b		2.13, m		2.13, m
12	24.5, CH ₂	1.90, m	24.5, CH ₂	1.90, m
13a	46.8, CH ₂	3.43, m	46.8, CH ₂	3.43, m
13b		3.65, ddd (4.5, 7.5, 9.8)		3.65, ddd (4.5, 7.5, 9.8)
14	171.6, C		171.6, C	
15	58.8, CH	3.57, dd (8.3, 10.0)	58.8, CH	3.57, dd (8.3, 10.0)
16	26.2, CH	2.33, m	26.2, CH	2.33, m
17	20.4, CH ₃	0.84, d (6.6)	20.4, CH ₃	0.84, d (6.6)
18	18.8, CH ₃	0.77, d (6.8)	18.8, CH ₃	0.77, d (6.8)
19	168.8, C		168.8, C	
20	52.2, CH	4.87 ddd (2.6, 8.0, 9.0)	52.2, CH	4.87 ddd (2.6, 8.0, 9.0)
21a	28.5, CH ₂	2.23, dd (2.6, 16.0)	28.4, CH₂	2.23, dd (2.6, 16.0)
21b		3.19, dd (9.0, 16.0)		3.19, dd (9.0, 16.0)
22	170.4, C		170.4, C	
23a	43.7, CH ₂	2.79, m	43.7, CH ₂	2.79, m
23b		3.28, m		3.28, m
24	41.0, CH	3.25, m	41.0, CH	3.25, m
25	61.7, CH	3.87, d (9.8)	61.7, CH	3.87, d (9.8)
26	167.7, C		167.7, C	
27	203.8, C		203.8, C	
28a	41.4, CH ₂	2.33, m	41.4, CH ₂	2.33, m
28b		2.44, dd (6.0, 16.6)		2.44, dd (6.0, 16.6)
29	23.1, CH ₂	1.44, m	23.1, CH ₂	1.44, m
30	28.7, CH ₂	1.20, m	28.5, CH₂	1.20, m
31	22.1, CH ₂	1.25, m	28.7, CH₂	1.25, m
32	28.8, CH ₂	1.23, m	28.9, CH₂	1.27, m
33	22.1, CH ₂	1.25, m	28.8, CH₂	1.23, m
34	31.3, CH ₂	1.23, m	31.3, CH ₂	1.23, m
35	28.9, CH ₂	1.27, m	22.1, CH₂	1.25, m
36	14.0, CH ₃	0.85, t (6.8)	14.0, CH ₃	0.85, t (6.8)
C1-NH		8.59, d (9.0)		8.59, d (9.0)
C7-NH		7.77, d (6.5)		7.77, d (6.5)
C15-NH		8.05, d (8.5)		8.05, d (8.5)
C20-NH		7.23, d (8.0)		7.23, d (8.0)
C23-NH		7.90, dd (5.3, 9.0)		7.90, dd (5.3, 9.0)



Fig. S1. HRESIMS of mutanobactin B (**2**).




Fig. S2. ^1H -NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S3. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S4. ^1H - ^{13}C HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S5. ^1H - ^{13}C HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S6. ^1H - ^1H COSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S7. ^1H - ^1H TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin B (**2**).




Fig. S8. ¹H-¹H NOESY-NMR spectrum (500 MHz, DMSO-*d*₆) of mutanobactin B (**2**).




Fig. S9. FTIR spectrum of mutanobactin B (2).




Fig. S10. HRESIMS of mutanobactin C (**3**).




Fig. S11. ¹H-NMR spectrum (500 MHz, DMSO-*d*₆) of mutanobactin C (**3**).




Fig. S12. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).




Fig. S13. ^1H - ^{13}C HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).




Fig. S14. ^1H - ^{13}C HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).




Fig. S15. ¹H-¹H COSY-NMR spectrum (500 MHz, DMSO-*d*₆) of mutanobactin C (**3**).




Fig. S16. ^1H - ^1H TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).




Fig. S17. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin C (**3**).




Fig. S18. FTIR spectrum of mutanobactin C (3).




Fig. S19. HRESIMS of mutanobactin D (**4**).




Fig. S20. ¹H-NMR spectrum (500 MHz, DMSO-*d*₆) of mutanobactin D (**4**).




Fig. S21. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S22. ^1H - ^{13}C HSQC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S23. ^1H - ^{13}C HMBC-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S24. ^1H - ^1H COSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S25. ^1H - ^1H TOCSY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S26. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin D (**4**).




Fig. S27. FTIR spectrum of mutanobactin D (4).




Fig. S28. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of $[1\text{-}^{13}\text{C}]$ acetate labeled mutanobactin A.




Fig. S29. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of $[2\text{-}^{13}\text{C}]$ acetate labeled mutanobactin A.




Fig. S30. ^{13}C -NMR spectrum (100 MHz, $\text{DMSO-}d_6$) of [^{15}N , $^{13}\text{C}_2$]glycine labeled mutanobactin

A.




Fig. S31. ¹H-NMR spectrum (500 MHz, DMSO-*d*₆) of mutanobactin A (**1**).




Fig. S32. ^1H - ^1H NOESY-NMR spectrum (500 MHz, $\text{DMSO-}d_6$) of mutanobactin A (**1**).




Fig. S33. FTIR spectrum of mutanobactin A (**1**).




Fig. S34. Marfey's analysis of FDAA derivatized amino acid standards for the D and L forms of Aaba, Ala, Ile, Leu, Pro, and Val (note that L-Aaba elutes under the FDAA peak under this elution condition).




Fig. S35. Marfey's analysis of FDAA derivatized hydrolysates of **2**.




Fig. S36. Marfey's analysis of FDAA derivatized hydrolysates of **3**.




Fig. S37. Marfey's analysis (gradient elution) of FDAA derivatized hydrolysates of **4** (note that L-Aaba elutes under the FDAA peak under this elution condition).





Fig. S38. Marfey's analysis (isocratic elution) of FDAA derivatized hydrolysates of **4**.




Fig. S39. Proposed biosynthetic pathways for the mutanobactins.